Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Journal of Endocrinological Investigation
Erschienen in:

01.06.2019 | Original Article

Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine

verfasst von: P. W. Rosario, G. Mourão, M. R. Calsolari

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study evaluated the recurrence rate in patients with papillary thyroid carcinoma (PTC) and minimal extrathyroidal extension (mETE) who had low thyroglobulin (Tg) after total thyroidectomy, and therefore, did not receive radioactive iodine (RAI).

Methods

This was a prospective study including 182 patients with tumors ≤ 4 cm and mETE without aggressive histology or clinically apparent lymph node involvement (cN0pNx). After thyroidectomy, all patients had nonstimulated Tg ≤ 0.3 ng/ml, negative antithyroglobulin antibodies (TgAb), and neck ultrasonography (US) showing no anomalies. Because of these results, the patients were not submitted to RAI.

Results

The time of follow-up ranged from 24 to 132 months (median 72 months). One hundred and seventy-eight patients (97.8%) continued to have nonstimulated Tg ≤ 0.3 ng/ml and negative US. Four patients (2.2%) exhibited an increase in Tg and lymph node metastases (structural recurrence). After surgery, these patients obtained nonstimulated Tg < 1 ng/ml and no apparent tumor was detected by the imaging methods.

Conclusion

The results suggest that patients with mETE and without other adverse features, who have low nonstimulated Tg and negative neck US after thyroidectomy, do not require ablation with RAI.
Literatur
1.
Nixon IJ, Ganly I, Patel S et al (2011) The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 150:1242–1249CrossRefPubMedPubMedCentral
2.
Hay ID, Johnson TR, Thompson GB, Sebo TJ, Reinalda MS (2016) Minimal extrathyroid extension in papillary thyroid carcinoma does not result in increased rates of either cause-specific mortality or postoperative tumor recurrence. Surgery 159:11–19CrossRefPubMed
3.
Yin DT, Yu K, Lu RQ, Li X, Xu J, Lei M (2016) Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma. Medicine (Baltimore) 95:e5794CrossRef
4.
Diker-Cohen T, Hirsch D, Shimon I et al (2018) Impact of minimal extra-thyroid extension in differentiated thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 103:2100–2106CrossRef
5.
Youngwirth LM, Adam MA, Scheri RP, Roman SA, Sosa JA (2017) Extrathyroidal extension is associated with compromised survival in patients with thyroid cancer. Thyroid 27:626–631CrossRefPubMed
6.
Orosco RK, Hussain T, Brumund KT, Oh DK, Chang DC, Bouvet M (2015) Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the surveillance, epidemiology, and end results database. Thyroid 25:125–132CrossRefPubMedPubMedCentral
7.
Castagna MG, Forleo R, Maino F et al (2018) Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. J Endocrinol Invest 41:1029–1035CrossRefPubMed
8.
Yu XM, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660CrossRefPubMed
9.
Nilubol N, Kebebew E (2015) Should small papillary thyroid cancer be observed? A population-based study. Cancer 121:1017–1024CrossRefPubMed
10.
Perros P, Boelaert K, Colley S, British Thyroid Association et al (2014) Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 81(Suppl 1):1–122CrossRef
11.
Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133CrossRefPubMedPubMedCentral
12.
Lepoutre-Lussey C, Deandreis D, Leboulleux S, Schlumberger M (2014) Postoperative radioactive iodine administration for differentiated thyroid cancer patients. Curr Opin Endocrinol Diabetes Obes 21:363–371CrossRefPubMed
13.
Zerdoud S, Giraudet AL, Leboulleux S et al (2017) Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. Ann Endocrinol (Paris) 78:162–175CrossRef
14.
Pacini F, Basolo F, Bellantone R et al (2018) Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Investig 41:849–876CrossRef
15.
Buffet C, Golmard JL, Hoang C et al (2012) Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol 167:267–275CrossRefPubMed
16.
Verburg FA, Mäder U, Reiners C, Hänscheid H (2014) Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab 99:4487–4496CrossRefPubMed
17.
Chu KP, Baker S, Zenke J et al (2018) Low activity radioactive iodine therapy for thyroid carcinomas exhibiting nodal metastases and extrathyroidal extension may lead to early disease recurrence. Thyroid 28:902–912CrossRefPubMed
18.
19.
Momesso DP, Vaisman F, Yang SP et al (2016) Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J Clin Endocrinol Metab 101:2692–2700CrossRefPubMedPubMedCentral
20.
Park S, Kim WG, Song E et al (2017) Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy. Thyroid 27:524–530CrossRefPubMed
21.
Mourão GF, Rosario PW, Calsolari MR (2016) Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation. Endocr Relat Cancer 23:47–52CrossRefPubMed
22.
Rosario PW, de Faria S, Bicalho L, Alves MF et al (2005) Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 24:1385–1389CrossRefPubMed
23.
Rosario PW, Tavares WC, Borges MA, Santos JB, Calsolari MR (2014) Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study. Endocr Pract. 20:293–298CrossRefPubMed
24.
Rosario PW, Mourão GF, Siman TL, Calsolari MR (2015) Serum thyroglobulin measured with a second-generation assay in patients undergoing total thyroidectomy without radioiodine remnant ablation: a prospective study. Thyroid 25:769–775CrossRefPubMed
25.
Rosario PW, Maia FF, Fagundes TA, Vasconcelos FP, Cardoso LD, Purisch S (2004) Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq Bras Endocrinol Metabol. 48:487–492CrossRefPubMed
26.
Tuttle M, Morris LF, Haugen B et al (2017) Thyroid—differentiated and anaplastic carcinoma (Chapter 73). In: Amin MB, Edge SB, Greene F et al (eds) AJCC cancer staging manual, 8th edn. Springer International Publishing, New York
27.
Sapuppo G, Palermo F, Russo M et al (2017) Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome. J Endocrinol Invest 40:1355–1363CrossRefPubMed
28.
Robenshtok E, Grewal RK, Fish S, Sabra M, Tuttle RM (2013) A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. Thyroid 23:436–442CrossRefPubMed
29.
Matrone A, Gambale C, Piaggi P et al (2017) Postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform 131I ablation. J Clin Endocrinol Metab 102:893–902PubMed
30.
Rosario PW, Mourão GF, Calsolari MR (2016) Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk ‘with higher risk features’. Clin Endocrinol (Oxf) 85:453–458CrossRef
31.
Rosario PW, Xavier AC, Calsolari MR (2011) Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21:49–53CrossRefPubMed
32.
Rosario PW, Mourão GF, Siman TL, Calsolari MR (2015) A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low-risk papillary thyroid cancer patients: implication for radioiodine indication. Clin Endocrinol (Oxf) 83:957–961CrossRef
33.
Rosario PW, de Furtado MS, Calsolari MR (2015) Patients with papillary thyroid carcinoma at intermediate risk of recurrence according to american thyroid association criteria can be reclassified as low risk when the postoperative thyroglobulin is low. Thyroid 25:1243–1248CrossRefPubMed
34.
Rosario PW, Mourão GF, Calsolari MR (2016) Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin. Nucl Med Commun 37:1024–1029CrossRefPubMed
35.
Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Calsolari MR (2012) Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22:1140–1143CrossRefPubMed
Metadaten
Titel
Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine
verfasst von
P. W. Rosario
G. Mourão
M. R. Calsolari
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 6/2019
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-018-0969-y

Weitere Artikel der Ausgabe 6/2019

Serum levels of adipokines in gestational diabetes: a systematic review

  • Review Article

Association of benign thyroid diseases with thyroid cancer risk: a meta-analysis of prospective observational studies

  • Original Article

Correction to: Cadmium exposure alters steroid receptors and proinflammatory cytokine levels in endothelial cells in vitro: a potential mechanism of endocrine disruptor atherogenic effect

  • Correction

The Mediterranean diet of an Italian worker of the sixteenth century portrayed by Annibale Carracci (1560–1609)

  • Endocrinology & Art

Relevance of TSH evaluation in elderly in-patients with non-thyroidal illness

  • Original Article

Evaluating the effects of mobile health intervention on weight management, glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus

  • Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise